Polyrizon Ltd. has announced positive results from a recent pre-clinical study evaluating its PL-14 Allergy Blocker, developed using the company's proprietary Capture & Contain (C&C) platform. The study assessed the formulation's ability to create a hydrogel barrier that limits the penetration of Der p 1, a major house dust mite allergen. Results showed that PL-14 significantly restricted allergen diffusion, with only 1.07% passing through after one hour, 1.14% after two hours, and 13.6% after four hours. The allergen concentrations used in the study were substantially higher than typical real-world exposures. The company plans to initiate clinical studies to further support regulatory and clinical development of PL-14 and other candidates within the C&C platform. The pre-clinical results have already been presented.